DNAe

DNAe is a private, pre-revenue diagnostics company developing a novel semiconductor-based next-generation sequencing (NGS) platform called LiDia-SEQ™. The platform is designed to deliver rapid, direct-from-specimen genomic analyses at the point-of-need, with an initial application targeting the critical unmet need for faster diagnosis of bloodstream infections and antimicrobial resistance. The company has significant non-dilutive funding from the US Biomedical Advanced Research and Development Authority (BARDA) and is advancing its lead program through late-stage development. DNAe's technology aims to bridge the gap between the speed of conventional assays and the rich information of traditional NGS, potentially revolutionizing patient care in sepsis and beyond.

LiDia-SEQ™, a semiconductor sequencing-based diagnostic platform that performs DNA analysis and electrical read-out on a single silicon microchip, enabling rapid, direct-from-specimen testing at the point-of-need.

DNAe competes with traditional blood culture systems, rapid multiplex PCR panels (e.g., from BioFire, Luminex), and other companies developing faster, simpler next-generation sequencing solutions. Its key differentiator is the combination of semiconductor-based NGS richness of information with point-of-need speed and simplicity, a niche currently with few direct competitors.